This point needs to be stressed
While semaglutide pens are designed for single-patient use and contain preservatives, using them beyond their safe timeframe increases contamination risk
Clinical features Beriberi: inadequate thiamine uptake due to malnutrition, heavy drinking, or increased demand (e.g., hyperthyroidism, pregnancy) Dry beriberi Symmetrical peripheral neuropathy (sensory and motor) Progressive muscle wasting Paralysis Confusion Wet beriberi High-output cardiac failure (due to systemic vasodilation) Dilated cardiomyopathy Cardiomegaly Edema Infantile beriberi: cardiomegaly, tachycardia, cyanosis, aseptic meningitis (vomiting and seizures) Wernicke encephalopathy Leigh syndrome Diagnostics: vitamin B 1 administration RBC transketolase activity In malnourished or alcohol-dependent patients, always administer thiamine before giving dextrose to decrease the risk of precipitating or exacerbating Wernicke encephalopathy
A: Pre-IRA, a drugs commercial NPV was modeled as: annual revenues under exclusivity discounted at WACC, multiplied by years of exclusivity
Such expansion of research protocol would provide a broader picture of the impact of caloric restriction and/or fasting combined with physical exercise on the human body health parameters
"Triple-Hormone-Receptor Agonist Retatrutide for Obesity." NEJM 2023;389:514526 FDA Prescription Drug User Fee Act (PDUFA) Guidelines FDA Center for Drug Evaluation and Research (CDER): NDA review process ClinicalTrials.gov: TRIUMPH Phase 3 program trial registry Historical obesity drug approval precedents: Semaglutide, Tirzepatide, Liraglutide Frequently Asked Questions Based on the current timeline, retatrutide FDA approval is expected in late 2027 to Q1 2028
